Takeda ups ulcerative colitis interests through Natrogen deal
This article was originally published in Scrip
Executive Summary
Takeda has licensed in comprehensive global rights to develop and commercialize Natura-alpha, a cytokine modulator for ulcerative colitis and other potential indications being developed by Natrogen Therapeutics International.